| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 |
|---|---|---|---|---|---|---|---|---|---|
Revenues: | |||||||||
Contract revenue | |||||||||
3,215 | 3,965 | 4,749 | - | - | - | - | - | - | - |
Grant revenue | |||||||||
1,414 | 1,275 | 683 | - | - | - | - | - | - | - |
Contract revenue | |||||||||
- | - | - | 10,448 | 8,641 | 5,545 | 565 | 0 | - | - |
License revenue | |||||||||
- | - | - | - | - | - | - | - | 5,000 | 0 |
Grant revenue | |||||||||
- | - | - | 0 | 127 | 1,497 | 2,658 | 3,144 | 2,662 | 1,947 |
Total revenues | |||||||||
4,629 | 5,241 | 5,432 | 10,448 | 8,768 | 7,043 | 3,224 | 3,144 | 7,662 | 1,947 |
Cost of revenues | |||||||||
3,567 | 4,597 | 4,310 | 8,433 | 6,882 | 5,313 | 2,544 | 2,593 | 2,108 | 1,638 |
Gross profit | |||||||||
1,062 | 643 | 1,122 | 2,015 | 1,886 | 1,729 | 679 | 551 | 5,554 | 309 |
Operating expenses: | |||||||||
Research and development | |||||||||
8,122 | 6,750 | 5,507 | 4,295 | 5,399 | 5,086 | 5,071 | 2,609 | 6,272 | 5,986 |
Acquired in-process research and development | |||||||||
- | - | - | - | - | 4,000 | 0 | - | - | - |
General and administrative | |||||||||
3,480 | 2,951 | 3,209 | 3,428 | 3,596 | 3,403 | 2,765 | 2,632 | 2,242 | 2,201 |
Total operating expenses | |||||||||
11,603 | 9,702 | 8,716 | 7,724 | 8,996 | 12,490 | 7,836 | 5,242 | 8,514 | 8,187 |
Loss from operations | |||||||||
-10,541 | -9,058 | -7,593 | -5,709 | -7,110 | -10,761 | -7,156 | -4,690 | -2,960 | -7,878 |
Other income: | |||||||||
Foreign currency transaction (loss)/gain | |||||||||
-7 | 0 | - | - | - | - | - | - | - | - |
Change in fair value of warrant liability | |||||||||
- | - | - | -1,541 | 1,201 | -3,436 | 3,654 | - | - | - |
Gain on settlement liability | |||||||||
- | - | - | 390 | 0 | - | - | - | - | - |
Interest income | |||||||||
- | - | 29 | 2 | - | - | - | - | - | - |
Interest income (expense) | |||||||||
- | - | - | - | -8 | 1 | - | - | - | - |
Interest income | |||||||||
148 | 158 | - | - | - | - | 1 | 6 | 7 | 12 |
Research and development incentives | |||||||||
-433 | - | - | - | - | - | - | - | - | - |
Change in fair value of warrant liability | |||||||||
- | - | - | - | - | - | - | 0 | - | - |
Interest expense | |||||||||
- | - | - | - | - | - | - | - | - | 0 |
Other income, principally proceeds from QTDP grant | |||||||||
- | - | - | - | - | - | - | - | - | 234 |
Other income, net | |||||||||
- | - | - | 1,934 | -1,209 | 3,437 | -3,652 | 6 | 7 | 246 |
Net loss before income taxes | |||||||||
-9,966 | -8,899 | -7,563 | -3,775 | -8,320 | -7,323 | -10,809 | -4,684 | -2,952 | - |
Net loss before income taxes | |||||||||
- | - | - | - | - | - | - | - | - | -7,632 |
Income tax benefit | |||||||||
-610 | - | -416 | -530 | -488 | -616 | -750 | -521 | -574 | -245 |
Net loss | |||||||||
-9,355 | -8,899 | -7,147 | -3,245 | -7,831 | -6,706 | -10,058 | -4,163 | -2,378 | - |
Basic net loss per share | |||||||||
- | - | - | -0.93 | -3.00 | -3.25 | -0.65 | - | - | - |
Diluted net loss per share | |||||||||
- | - | - | -1.34 | -3.00 | -4.30 | -0.65 | - | - | - |
Basic weighted average common shares outstanding | |||||||||
- | - | - | 3,481 | 2,606 | 2,063 | 15,463 | - | - | - |
Diluted weighted average common shares outstanding | |||||||||
- | - | - | 3,583 | 2,606 | 2,358 | 15,463 | - | - | - |
Net (loss) income | |||||||||
- | - | - | - | - | - | - | - | - | -7,386 |
Basic and diluted net loss per share | |||||||||
-0.48 | -0.68 | -1.16 | - | - | - | - | -0.37 | -0.22 | -0.73 |
Basic and diluted weighted average common shares outstanding | |||||||||
19,376 | 13,178 | 6,144 | - | - | - | - | 11,136 | 10,957 | - |
Basic and diluted weighted average common shares outstanding | |||||||||
- | - | - | - | - | - | - | - | - | 10,120 |